摘要
目的探讨常规抗心力衰竭药物与β受体阻滞剂合用对心力衰竭的作用及安全性。方法将本院2018年2月—2019年2月收治的100例心力衰竭患者纳入研究,随机分成对照组(n=50)和观察组(n=50),对照组采取常规抗心力衰竭药物治疗,观察组采取常规抗心力衰竭药物治疗联合β受体阻滞剂治疗,观察两组患者的治疗效果以及不良反应发生情况。结果观察组的总有效率(92.00%)较对照组(70.00%)更高,χ^2=7.862,P=0.005;观察组的不良反应发生率(6.00%)与对照组的不良反应发生率(4.00%)相比差异无统计学意义,χ^2=0.211,P=0.646。结论常规抗心力衰竭药物联合β受体阻滞剂治疗心力衰竭能显著提高临床疗效,且不增加不良反应情况的发生。
Objective To explore the effect and safety of conventional antiheart failure drugs combined withβ-blockers on heart failure.Methods A total of 100 patients with heart failure treated in our hospital from February 2018 to February 2019 were included in the study and randomly divided into a control group(n=50)and an observation group(n=50).The control group was treated with conventional anti-heart failure drugs.In the treatment,the observation group was treated with conventional anti-heart failure drugs combined withβ-blockers.The treatment effects and adverse reactions of the two groups were observed.Results The total effective rate in the observation group(92.00%)was higher than the control group(70.00%)(χ^2=7.862,P=0.005);the incidence of adverse reactions in the observation group(6.00%)and the incidence of adverse reactions in the control group(4.00%)compared with no significant difference(χ^2=0.211,P=0.646).Conclusion Conventional anti-heart failure drugs combined withβ-blockers can significantly improve the clinical efficacy of heart failure without increasing the incidence of adverse reactions,which is worthy of clinical popularization.
作者
阿依帕夏·艾沙
Ayipaxia•Aisha(Second Department of Coronary Heart Disease,Xinjiang Kashgar Area First People's Hospital,Kashgar Xinjiang 844000,China)
出处
《中国卫生标准管理》
2020年第10期80-82,共3页
China Health Standard Management